What is claimed is:

1. A compound having Formula **I**:



I

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each C_{1-3} alkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{4-8} heterocyclo,

R^4 is selected from the group consisting of C_{1-4} alkyl, and C_{3-6} cycloalkyl;

R^5 is halo;

R^6 is selected from the group consisting of C_{1-4} alkyl, and C_{3-6} cycloalkyl; and

R^7 is selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{3-6} cycloalkyl,

with proviso that when R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each hydrogen, then R^3 is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclo.

2. The compound of claim 1 having Formula **II**:



II

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each C_{1-3} alkyl; and

R^3 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{4-8} heterocyclo.

3. The compound of claims 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each methyl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is hydrogen.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is C_{1-3} alkyl.

6. The compound of claim 5, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is methyl.

7. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is C_{3-6} heterocyclo.

8. The compound of claim 7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is selected from the group consisting of:



9. A pharmaceutical composition comprising the compound of any one of claims 1-8, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.

10. Use of a therapeutically effective amount of the compound of any one of claims 1-8, or a pharmaceutically acceptable salt, hydrate, or solvate thereof in the manufacture of a medicament for treating a patient having cancer, a chronic autoimmune disorder, an inflammatory condition, or a proliferative disorder.

11. The use of claim 10, wherein the patient has cancer.

12. The use of claim 11, wherein the cancer is selected from the group consisting of anaplastic large-cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumors, neuroblastoma, anaplastic thyroid cancer, rhabdomyosarcoma, breast cancer, colorectal cancer, esophageal squamous cell cancer, and renal cell carcinoma.

13. The pharmaceutical composition of claim 9 for use in therapy.

14. The pharmaceutical composition of claim 13 for use in treating cancer, a chronic autoimmune disorder, an inflammatory condition, or a proliferative disorder.

15. The pharmaceutical composition for use according to claim 14, wherein the cancer is selected from the group consisting of anaplastic large-cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumors, neuroblastoma, anaplastic thyroid cancer, rhabdomyosarcoma, breast cancer, colorectal cancer, esophageal squamous cell cancer, and renal cell carcinoma.

16. A compound of any one of claims 1-8, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in treatment of cancer, a chronic autoimmune disorder, an inflammatory condition, or a proliferative disorder.

17. The compound of claim 16 for use in treating cancer.

18. The compound for use according to claim 17, wherein the cancer is selected from the group consisting of anaplastic large-cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumors, neuroblastoma, anaplastic thyroid cancer, rhabdomyosarcoma, breast cancer, colorectal cancer, esophageal squamous cell cancer, and renal cell carcinoma.

19. A kit comprising the compound of any one of claims 1-8, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and instructions for administration of the compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, to a patient having cancer, a chronic autoimmune disorder, an inflammatory condition, or a proliferative disorder.

20. The kit of claim 19, wherein the patient has cancer; optionally wherein the cancer is selected from the group consisting of anaplastic large-cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumors, neuroblastoma, anaplastic thyroid cancer, rhabdomyosarcoma, breast cancer, colorectal cancer, esophageal squamous cell cancer, and renal cell carcinoma.